Please use this identifier to cite or link to this item:
|Title:||Cardiovascular medicines : comparative costs and benefits|
Zarb Adami, Maurice
Azzopardi, Lilian M.
|Keywords:||Cardiovascular agents -- Costs -- Malta|
Cardiovascular agents -- Economic aspects
Generic drugs -- Malta
|Publisher:||University of Malta. Department of Pharmacy|
|Citation:||Cardona, M., Vella, J., Zarb Adami, M., Azzopardi, L. M., & Serracino-Inglott, A. (2013, August). Cardiovascular medicines: comparative costs and benefits. Poster session presented at the International Pharmaceutical Federation (FIP) World Congress, Dublin, Ireland.|
|Abstract:||A poster presentation regarding Cardiovascular medicines: comparative costs and benefits. Introduction: An increase in global life expectancy and a concomitant shift in population demographics is leading to a greater incidence of non-communicable disease, with cardiovascular(CVA) morbidity being the primary cause of death worldwide. In 2010, 17.3 million deaths and €863 million in healthcare interventions were attributed to CVA disease at a global level. With the same trends exhibiting themselves locally, consideration of the cost of treatment and financial factors was a topical issue. Aims: • Obtain the costs of all cardiovascular drugs found in the local private retail community setting • Analyse the prices of generic and proprietary products and derive a relationship • Observe the effect of a price differential for equivalent products to their sales volume over time.|
|Appears in Collections:||Scholarly Works - FacM&SPha|
Files in This Item:
|Cardiovascular_medicines_comparative_costs_and_benefits_2013.pdf||410.93 kB||Adobe PDF||View/Open|
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.